What is the equity of ImmuCell this year?
ImmuCell has equity of 24.99 M USD this year.
ImmuCell Equity 2024
ImmuCell Equity
24.99 M USD
Ticker
ICCC
ISIN
US4525253062
WKN
885825
In 2024, ImmuCell's equity was 24.99 M USD, a -17.73% increase from the 30.38 M USD equity in the previous year.
ImmuCell Aktienanalyse
What does ImmuCell do?
ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing ImmuCell's Equity
ImmuCell's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding ImmuCell's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating ImmuCell's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
ImmuCell's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in ImmuCell’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about ImmuCell stock
What was the equity of ImmuCell compared to the previous year?
The equity of ImmuCell has increased/decreased by -17.73% decreased compared to the previous year.
What impact does a high equity have on investors of ImmuCell?
A high equity is advantageous for investors of ImmuCell as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of ImmuCell?
A low equity can be a risk for investors of ImmuCell, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of ImmuCell affect the company?
An increase in equity of ImmuCell can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of ImmuCell affect the company?
A reduction in equity of ImmuCell can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of ImmuCell?
Some factors that can affect the equity of ImmuCell include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of ImmuCell so important for investors?
The equity of ImmuCell is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can ImmuCell take to change the equity?
To change equity, ImmuCell can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does ImmuCell pay?
Over the past 12 months, ImmuCell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmuCell is expected to pay a dividend of 0 USD.
What is the dividend yield of ImmuCell?
The current dividend yield of ImmuCell is .
When does ImmuCell pay dividends?
ImmuCell pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmuCell?
ImmuCell paid dividends every year for the past 0 years.
What is the dividend of ImmuCell?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmuCell located?
ImmuCell is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmuCell kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmuCell from 7/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/11/2024.
When did ImmuCell pay the last dividend?
The last dividend was paid out on 7/11/2024.
What was the dividend of ImmuCell in the year 2023?
In the year 2023, ImmuCell distributed 0 USD as dividends.
In which currency does ImmuCell pay out the dividend?
The dividends of ImmuCell are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImmuCell
Our stock analysis for ImmuCell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmuCell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
